Company intelligence / Profile preview
Therapex
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
Therapex has initiated a Phase 1/2 clinical trial of its lead asset TRX-221 for patients with EGFR-mutated non-small cell lung cancer who have developed resistance to third-generation therapies like Tagrisso. The program aims to address multiple resistance mutations with high blood-brain barrier permeability. Preclinical models showed strong efficacy in tumor remission compared to competitors.[3]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugates (ADC)Proteolysis-targeting chimeras (PROTAC)[4][5]
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Therapex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therapex.